November MIMS Update

Some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Dapagliflozin (propanediol monohydrate) and sitagliptin (phosphate monohydrate) (Sidapvia) is a combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, and the dipeptidyl peptidase 4 (DPP4) inhibitor, sitagliptin, with distinct and complementary mechanisms of action to improve glycaemic control.